• Reduces HbA1c with reductions in hypoglycemia events, increased time within target glucose range (TIR), and reductions in time below range

  • Significantly reduces glycemic variability and the time spent in hypoglycemia among T2D adults treated with intensive insulin therapy

  • A strong link between CGM use and reductions in hospitalizations for DKA and severe hypoglycemia has also been reported

  • Also, use of CGM has potential benefits in managing cardiovascular disease and patients with ESRD

  • The Ambulatory Glucose Profile (AGP) report allow a consistent visualization format (numerical and graphs) for rapid identification of most significant glucose patterns to guide therapy decisions and enhance patient-clinician collaboration

  • Virtual telehealth visits combined with remotely monitoring CGM improves glycemic control, reduces diabetes-distress, and enhances patients’ adherence to prescribed therapy, with increased time and cost-efficiency vs in-clinic diabetes care

MAT-BH-2200913/V1/Nov 2022